Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jaguar Health Inc
(NQ:
JAGX
)
0.9847
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
131
Open
0.9847
Bid (Size)
0.9500 (45)
Ask (Size)
0.9847 (3)
Prev. Close
0.9847
Today's Range
0.9847 - 0.9847
52wk Range
0.9000 - 24.30
Shares Outstanding
171,350,166
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
November 19, 2024
Via
ACCESSWIRE
Earnings Scheduled For November 13, 2024
November 13, 2024
Via
Benzinga
Performance
YTD
-89.15%
-89.15%
1 Month
-15.84%
-15.84%
3 Month
-19.94%
-19.94%
6 Month
-80.81%
-80.81%
1 Year
-95.21%
-95.21%
More News
Read More
Jaguar Health Reports Third Quarter 2024 Financial Results
November 13, 2024
Via
ACCESSWIRE
Exploring Jaguar Health's Earnings Expectations
November 12, 2024
Via
Benzinga
Lisa Conte, CEO of Jaguar Health Inc. (NASDAQ: JAGX), to Present at NobleCon20
November 12, 2024
Via
Investor Brand Network
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
November 11, 2024
Via
ACCESSWIRE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
November 06, 2024
Via
ACCESSWIRE
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
October 16, 2024
Via
ACCESSWIRE
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
September 04, 2024
Via
ACCESSWIRE
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
August 27, 2024
Via
ACCESSWIRE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
August 19, 2024
Via
ACCESSWIRE
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
November 04, 2024
Via
ACCESSWIRE
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
October 29, 2024
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
Via
ACCESSWIRE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
October 10, 2024
Via
ACCESSWIRE
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
October 08, 2024
Via
ACCESSWIRE
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
October 01, 2024
Via
ACCESSWIRE
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and
September 26, 2024
Via
ACCESSWIRE
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 25, 2024
Via
ACCESSWIRE
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
September 24, 2024
Via
ACCESSWIRE
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
September 16, 2024
Via
ACCESSWIRE
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
September 10, 2024
Via
ACCESSWIRE
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
September 06, 2024
Via
ACCESSWIRE
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
September 05, 2024
Via
ACCESSWIRE
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
August 20, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.